Employed by the Company as a Principal Scientist, Analytical Development, with compensation for fiscal 2025.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Matthew B. Klein, M.D., M.S., F.A.C.S.
Also a director
CHIEF EXECUTIVE OFFICER
Title from the Form 4 dated Aug 4, 2026
|
54 | Not stated | Not stated | $23,266,326 | |
|
Pierre Gravier
Chief Financial Officer
|
41 |
Since 2023
3 years
|
Not stated | $3,550,786 | |
|
Neil Almstead
Chief Technical Operations Officer
|
59 |
Since 2018
8 years
|
2000 | $3,159,055 | |
|
Mark E. Boulding
Executive Vice President and Chief Legal Officer
|
65 |
Since 2012
14 years
|
2002 | Not reported | |
|
Lee Golden, M.D.
Executive Vice President and Chief Medical Officer
|
58 |
Since 2023
3 years
|
Not stated | $3,269,179 | |
|
Eric Pauwels
Chief Business Officer
|
65 |
Since 2020
6 years
|
2015 | $3,562,968 | |
|
Christine Utter
SVP, CHIEF ACCOUNTING OFFICER
Title from the Form 4 dated Jun 17, 2026
|
48 | Not stated | 2010 | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 20, 2026 · updated by the 8-Ks of Jun 9, 2026 and Jul 30, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Michael Schmertzler
Board chair
|
74 |
2001
25 years
|
Independent |
Development Committee
|
None stated | $896,310 | |
|
Matthew B. Klein, M.D., M.S., F.A.C.S.
CEO
|
54 |
2023
3 years
|
Not stated | None stated | ClearPoint Neuro, Inc. | Paid as CEO | |
|
Stephanie S. Okey, M.S.
|
66 |
2018
8 years
|
Independent | None stated | Crinetics Pharmaceuticals, Inc. | $471,905 | |
|
Jerome B. Zeldis, M.D., Ph.D.
|
76 |
2012
14 years
|
Independent |
Nominating and Corporate Governance Committee
|
Soligenix, Inc. | $463,905 | |
|
Emma Reeve
|
65 |
2018
8 years
|
Independent |
Audit Committee · Chair
|
Whitehawk Therapeutics, Inc. | $507,405 | |
|
Mary Smith
|
63 |
2021
5 years
|
Independent |
Audit Committee
|
None stated | $479,405 | |
|
Glenn D. Steele Jr., M.D., Ph.D.
|
81 |
2015
11 years
|
Independent |
Compensation Committee · Chair
|
None stated | $477,405 | |
|
Allan Jacobson, Ph.D.
|
80 |
1998
28 years
|
Independent |
Development Committee · Chair
|
None stated | $547,405 | |
|
David P. Southwell
|
65 |
2005
21 years
|
Independent |
Compensation Committee
|
Rocket Pharmaceuticals | $494,405 | |
|
Hege Sollie-Zetlmayer
Joined Jul 28, 2026
|
- | - | - | - | - | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Employed by the Company as a Principal Scientist, Analytical Development, with compensation for fiscal 2025.
Company acquired substantially all assets of BioElectron under an Asset Purchase Agreement; Dr. Klein owns about six percent of BioElectron and is entitled to a portion of payments made to BioElectron under that agreement.
Indemnification agreements under which the Company may indemnify directors and executive officers for expenses, judgments, fines and settlement amounts arising from their service.
Loading...